Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation

被引：0

作者：

Patel, S. ^{[1
]}

Zhao, S. ^{[2
]}

Wei, L. ^{[2
]}

Li, M. ^{[3
]}

Bertino, E. ^{[3
]}

Presley, C. ^{[3
]}

Welliver, M. ^{[3
]}

Haglund, K. ^{[3
]}

Palmer, J. ^{[3
]}

Arnett, A. ^{[3
]}

Beyer, S. ^{[3
]}

Mende, E. ^{[3
]}

Elder, J. ^{[3
]}

Hardesty, D. ^{[3
]}

Shields, P. ^{[4
]}

Carbone, D. ^{[4
]}

Otterson, G. ^{[4
]}

Williams, T. ^{[3
]}

Owen, D. ^{[4
]}

机构：

[1] Ohio State Univ, Ctr Comprehens Canc, Hematol Med Oncol, Columbus, OH 43210 USA

[2] Ohio State Univ, Ctr Comprehens Canc, Biostat, Columbus, OH 43210 USA

[3] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[4] Ohio State Univ, Ctr Comprehens Canc, Med Oncol, Columbus, OH 43210 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期

关键词：

Stage III NSCLC; Brain Metastasis; Durvalumab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P21.02

引用

页码：S363 / S364

页数：2

共 50 条

[1] The Incidence of Brain Metastasis and Radiation Pneumonitis With Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC
Kim, Y.
Choi, Y-K
Kwak, Y-K
Lee, Y-H
Kim, S-H
Sung, S-Y
Son, S-H
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S281 - S281
[2] Durvalumab Approved for Unresectable Stage 3 NSCLC After Chemoradiation
Schuyler, Devon
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 273 - 273
[3] Elderly patients with unresectable stage 3 NSCLC treated with definitive chemoradiation with or without durvalumab: Safety and outcomes.
Ryan, Malcolm Isaiah
Weiss, Jessica
Fares, Aline Fusco
Tsao, Ming Sound
Liu, Geoffrey
Bradbury, Penelope Ann
Leighl, Natasha B.
Shepherd, Frances A.
Sacher, Adrian G.
Lau, Sally C. M.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] Real-World Outcomes of Stage III NSCLC Treated with Chemoradiation plus /- durvalumab
Duan, R.
Kordon, A.
Kwan, M.
Yadav, P.
Thomas, T. O.
Abazeed, M.
Gharzai, L. A.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (01): : E11 - E11
[5] Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
Lau, Sally C. M.
Ryan, Malcolm
Weiss, Jessica
Fares, Aline Fusco
Garcia, Miguel
Schmid, Sabine
Kuang, Shelley
Kelly, Deirdre
Tsao, Ming Sound
Bradbury, Penelope A.
Cho, Byoung Chun J.
Sun, Alexander
Raman, Srinivas
Hope, Andrew
Giuliani, Meredith
Lok, Benjamin H.
Bezjak, Andrea
Liu, Geoffrey
Leighl, Natasha B.
Shepherd, Frances A.
Sacher, Adrian G.
JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (12):
[6] Identification of predictive factors for early relapse in patients with unresectable stage III NSCLC receiving consolidation durvalumab after concurrent chemoradiation
Yeo, Chang Dong
Kang, Hye Seon
Kim, In Kyoung
Lee, Sang Haak
Kim, Jin Woo
CANCER RESEARCH, 2023, 83 (07)
[7] Identification of predictive factors for early relapse in patients with unresectable stage III NSCLC receiving consolidation durvalumab after concurrent chemoradiation
Nam, Jung Hyun
Yeo, Chang Dong
Park, Chan Kwon
Kim, Sung Kyoung
Kim, Ju Sang
Kim, Yong Hyun
Kim, Jin Woo
Kim, Seung Joon
Lee, Sang Hak
Kang, Hye Seon
RESPIROLOGY, 2023, 28 : 98 - 98
[8] Real-world outcomes with durvalumab (durva) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC (SPOTLIGHT)
Mooradian, M.
Allen, A.
Cai, L.
Xiao, Y.
Chander, P.
ANNALS OF ONCOLOGY, 2022, 33 : S86 - S86
[9] DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy
Filippi, Andrea R.
Dziadziuszko, Rafal
Garcia Campelo, Maria Rosario
Paoli, Jean-Baptiste
Sawyer, William
Diaz Perez, Ignacio Esteban
FUTURE ONCOLOGY, 2021, 17 (34) : 4657 - 4663
[10] Durvalumab After Chemoradiotherapy for Patients With Unresectable Stage III NSCLC: The PACIFIC-R Study
Zhao, Binghao
Li, Huanzhang
Ma, Wenbin
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : e38 - e39

← 1 2 3 4 5 →